1

# <sup>1</sup> Maternal obesity, interpregnancy weight changes and congenital

# 2 heart defects in the offspring: a nationwide cohort study

- 3 Gitte HEDERMANN, MD<sup>\*1,2,3</sup>; Ida N THAGAARD, MD, PhD<sup>1,4</sup>; Paula L HEDLEY, PhD, MPH<sup>1</sup>; Lone
- 4 KREBS, MD, DMSc<sup>5,6</sup>; Christian M HAGEN, MSc<sup>1</sup>; Thorkild I A SØRENSEN, MD, DMSc<sup>7,8</sup>; Michael

5 CHRISTIANSEN, MD, FRCPath<sup>1,9</sup>; Charlotte K EKELUND, MD, PhD<sup>6,10</sup>

- 6
- <sup>7</sup> <sup>1</sup> Department for Congenital Disorders, Danish National Biobank and Biomarkers, Statens Serum
- 8 Institut, Copenhagen, Denmark
- 9 <sup>2</sup> Department of Obstetrics and Gynecology, Copenhagen University Hospital, Rigshospitalet,
- 10 Copenhagen, Denmark
- <sup>3</sup> Department of Obstetrics and Gynecology, Slagelse Hospital, Denmark
- <sup>4</sup> Department of Obstetrics and Gynecology, Nordsjaellands Hospital, Denmark
- <sup>5</sup> Department of Obstetrics and Gynecology, Copenhagen University Hospital, Amager and
- 14 Hvidovre Hospital, Copenhagen, Denmark
- <sup>6</sup> Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- <sup>7</sup> Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen,
- 17 Denmark
- <sup>8</sup> The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and
- 19 Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- <sup>9</sup> Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

 $\label{eq:matrix} \textbf{Maternal obesity and CHDs in the offspring}$ 

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

21 <sup>10</sup> Ce	enter of Fetal Medicine,	Department of Obstetrics,	Copenhagen University Hospital,
---------------------	--------------------------	---------------------------	---------------------------------

- 22 Rigshospitalet, Copenhagen, Denmark
- 23

24 Disclosures: The authors report no conflict of interest

- 25
- Funding: This study was supported by The Danish Children Heart Foundation (18-R109-A5193-
- 27 26043), The A.P. Moller Foundation (19-L-0096), and Aase and Ejnar Danielsen's Foundation (19-
- 28 10-0493). This research has been conducted using the Danish National Biobank resource
- supported by the Novo Nordisk Foundation. The funders had no role in study design, data
- 30 collection and analysis, decision to publish, or preparation of the manuscript.
- 31
- 32 Paper presentation information: Part of the data has been presented at the 31st World Congress
- 33 on Ultrasound in Obstetrics and Gynecology 2021 (Virtual, 15-17 October:
- 34 https://obgyn.onlinelibrary.wiley.com/doi/10.1002/uog.23862) and 32nd World Congress on
- 35 Ultrasound in Obstetrics and Gynecology 2022 (London, 16-18 September:
- 36 https://doi.org/10.1002/uog.25154).
- 37
- 38 Corresponding author: Gitte Hedermann, Department for Congenital Disorders, Danish National
- 39 Biobank and Biomarkers, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark,
- 40 phone: +45 2081 0261, e-mail: gihc@ssi.dk

3

41

## 42 Word count: abstract (492 words); main text (2 848 words)

#### 4

## 43 Condensation

- 44 Tweetable statement: The risk of fetal congenital heart defect is associated with high maternal
- 45 BMI, and it may also be affected by a substantial weight gain between pregnancies.

46

47 Short Title: Maternal obesity and CHDs in the offspring

48

#### 49 AJOG at a Glance

- 50 A. Why was this study conducted?
- None of the large cohort studies on the association between maternal BMI and congenital
- 52 heart defects (CHDs) have included the proportion of CHDs that are identified in
- 53 terminated pregnancies.
- No previous studies have investigated the association between interpregnancy weight
- 55 changes and CHDs.

56

- 57 B. What are the key findings?
- Risk of CHDs became gradually higher with higher maternal BMI when including live births,
- 59 stillbirths, abortions and terminated pregnancies.
- A trend was found between interpregnancy weight gain and risk of CHDs.

61

62 C. What does this study add to what is already known?

- The association between high maternal BMI and risk of CHDs are not caused by a lower
- 64 detection rate of fetal CHDs in pregnant women with obesity.

6

## 65 Abstract

66	Background: Maternal obesity has been positively associated with increased risk of congenital
67	heart defects in the offspring. However, none of the large studies have included the considerable
68	proportion of congenital heart defects that are identified due to improvements in prenatal
69	diagnostics and terminated in pregnancy. The mechanism behind the association is poorly
70	understood, and a relation to interpregnancy weight changes is to be investigated.
71	Objectives: To evaluate the association between maternal obesity and congenital heart defects in
72	the offspring when including all pregnancies and to investigate if interpregnancy weight change
73	between the first and second pregnancy influences risk of fetal congenital heart defects.
74	Study Design: A nationwide cohort study of all singleton pregnancies in Denmark from 2008 to
75	2018. All data on maternal and offspring characteristics were retrieved from the Danish Fetal
76	Medicine Database. The database included data on postnatal diagnoses of congenital heart
77	defects in live births and prenatal diagnoses of congenital heart defects from ultrasound
78	examinations during pregnancy resulting in live birth, stillbirth, spontaneous abortion after
79	gestational week 12 or termination of pregnancies after gestational week 12. As this cohort
80	encompassed all pregnancies over a 10-year period, it was possible for women to experience
81	multiple pregnancies. Congenital heart defects and severe congenital heart defects were grouped
82	according to European Surveillance of Congenital Anomalies' definitions. Children or fetuses with
83	chromosomal aberrations were excluded. Relative risks were calculated using log-linear Poisson
84	models for congenital heart defects overall, severe congenital heart defects and for five of the
85	most prevalent subtypes of congenital heart defects.

86	Results: Of the 547 178 pregnancies included in the cohort, 5 498 had congenital heart defects
87	(1.0%). Risk of congenital heart defects became gradually higher with higher maternal BMI; for
88	BMI 30-34.9 kg/m <sup>2</sup> , adjusted relative risk = 1.23 (95% confidence interval 1.12-1.36), for BMI 35-
89	39.9 kg/m <sup>2</sup> , adjusted relative risk = 1.26 (95% confidence interval 1.09-1.46) and for BMI $\ge$ 40
90	kg/m <sup>2</sup> , adjusted relative risk = 1.81 (95% confidence interval 1.50-2.15). Data was adjusted for
91	maternal age, smoking status and year of estimated due date. The same pattern was seen for the
92	subgroup of severe congenital heart defects. Among the atrioventricular septal defects (n = 245), a
93	particularly strong association with maternal BMI $\geq$ 40 kg/m <sup>2</sup> was seen, adjusted relative risk =
94	4.19 (95% confidence interval 2.13-7.42). 107 627 women were identified with their first and
95	second pregnancies in the cohort. Interpregnancy BMI change was positively, albeit not
96	statistically significant, associated with risk of congenital heart defects in the second pregnancy
97	when adjusting for maternal age and BMI, with an adjusted relative risk = 1.27 (95% confidence
98	interval 0.96-1.64) among persons with a BMI increase of $\geq$ 4 kg/m <sup>2</sup> .
99	Conclusions: When including both pre- and postnatally diagnosed congenital heart defects, this
100	study showed a positive dose-response association between maternal BMI and risk of congenital
101	heart defects in the offspring. However, only a non-significant trend was seen between
102	interpregnancy BMI changes and risk of congenital heart defects in the second pregnancies.
103	
104	Keywords: atrioventricular septum defect; coarctation of the aorta; epidemiological study;
105	maternal BMI; prenatal congenital heart defects; register-based study; severe congenital heart
106	defects; The Danish Fetal Medicine database; Tetralogy of Fallot; transposition of the great
107	arteries; univentricular heart

8

## 108 Introduction

109	Obesity among women of reproductive age has been increasing over the last three decades. <sup>1</sup>
110	Centers for Disease Control and Prevention estimated that 40% of women aged 20-39 years old in
111	the United States were obese (body mass index [BMI] $\ge$ 30 kg/m <sup>2</sup> ) in 2017-2018. <sup>2</sup> Maternal obesity
112	is a risk factor for adverse pregnancy outcomes as well as for long-term health consequences for
113	both the mother and child. <sup>3,4</sup> Furthermore, maternal obesity is positively associated with risk of
114	having a child with congenital malformations. <sup>5</sup>
115	Congenital heart defects (CHDs) remain the leading cause of infant death from congenital
116	malformations in the United States. <sup>6</sup> Believed to be the most common congenital malformations,
117	CHDs have a global prevalence of nine per 1000 live births with geographical differences. <sup>7</sup> The
118	causes of CHDs are unknown in most cases, but are associated with maternal chronic conditions,
119	viral infections and fetal exposures to teratogenic drugs. <sup>8-10</sup> Conflicting evidence of an association
120	between maternal age and fetal CHDs persist, but a recent large European study found a positive
121	association between both young- and older maternal age and total prevalence of CHDs. <sup>11</sup> With
122	improvements in genetic and genomic analytical techniques an increasing number of genetic
123	associations/causes have been identified in up to 30% of the cases. <sup>12</sup>
124	The association between maternal obesity and infants born with congenital malformations has
125	been reported to include CHDs. However, none of the large studies have included the proportion

of CHDs that are identified and terminated in pregnancy. During the last two decades, the prenatal

identification of CHDs have increased dramatically, consequently, an analysis of the association

between maternal risk factors and CHDs should include data on prenatally identified cases. Meta-

analyses suggest a moderate association between maternal obesity (BMI  $\ge$  30 kg/m<sup>2</sup>) and CHDs in

9

the offspring with an odds ratio (OR) = 1.2 (95% confidence interval [CI] 1.1–1.2)<sup>13</sup> or an OR = 1.3
(95% CI 1.2–1.4).<sup>14</sup> A recent systematic review on the topic demonstrated great heterogeneity
among the studies with respect to design, exposure definition, outcome definition, choice of
covariates, and only populations of Northern European or Chinese descent were examined to a
reasonable extent.<sup>15</sup>

135 Some studies have found an association between maternal interpregnancy BMI changes and adverse pregnancy- and perinatal outcomes that were linearly related to the amount of weight 136 gain.<sup>16,17</sup> So far, a few small studies suggest that this might be relevant for certain congenital 137 malformations (spina bifida, gastroschisis and oral cleft),<sup>16,18-20</sup> however, no data is available in 138 these studies for fetal CHDs. It is of great importance to identify any modifiable risk factors for 139 CHDs. If weight gain, defined as interpregnancy BMI change, is associated with CHDs, this could be 140 added to the etiology of the association and the justification of preventive initiatives as to stress 141 weight stability, and for some women weight loss. 142

This study aims to assess the risk of fetal CHDs, severe CHDs or five of the most frequently
identified subtypes of CHDs according to early-pregnancy BMI. The study population comprises all
CHDs found among live births, stillbirths, abortions and terminated pregnancies in Denmark. The
study also investigates if changes in maternal BMI from the beginning of the first pregnancy to the
beginning of the second pregnancy were associated with risk of CHDs in the second pregnancy.

148 Materials and Methods

This cohort study was performed on prospectively collected data retrieved from a nationwide
 cohort based on The Danish Fetal Medicine Database.<sup>21</sup> The Danish Fetal Medicine Database
 includes data on pregnancies with prenatal screening results from all obstetric and gynecological

10

departments in Denmark from January 1, 2008.<sup>21</sup> All women in Denmark are offered a first 152 trimester screening for chromosomal abnormalities (gestational week 12) and a second trimester 153 154 anomaly scan, for which the uptake rate is high; 95% of pregnant women participate. The 155 database does not include data on outcomes of pregnancies before the first trimester scan. The 156 primary source of information is the local fetal medicine databases used nationwide. The Danish 157 Fetal Medicine Database includes data on maternal characteristics including weight and height, data from ultrasound examinations and pregnancy outcomes.<sup>21</sup> Furthermore, the database 158 includes data from other Danish registers: the Danish Cytogenetic Central Register,<sup>22</sup> the Danish 159 National Patient Register,<sup>23</sup> and the Danish Medical Birth Register.<sup>24</sup> All Danish residents are 160 161 assigned a unique personal identification number enabling linkage of data between national registers and other data sources.<sup>25</sup> In Denmark, health care is free and and it is standard practice 162 to offer genetic testing by chorionic villus sampling or amniocentesis when a CHD is diagnosed 163 prenatally.<sup>26</sup> The prenatal detection rate of major CHD is high and the majority of parents opt for 164 further testing.<sup>27,28</sup> A gradual transition from conventional karyotyping to chromosomal 165 166 microarray was observed over the course of the study period. Postnatal genetic testing primarily by chromosomal microarray is performed in all children with syndromic suspicion. The Danish 167 Fetal Medicine database is updated once a year with information on postnatal diagnosed 168 congenital malformations and karyotypes.<sup>21</sup> The International Classification of Diseases, 10th 169 revision code system (ICD-10) is used to code malformations in the fetus and in the infant.<sup>21</sup> 170 The cohort included singleton pregnancies in Denmark with an estimated due date, from 171 ultrasound scan, between June 1, 2008 and June 1, 2018. Each woman can have multiple 172 pregnancies during the study period. Pregnancies with a fetus or child with a chromosomal 173 174 aberration were excluded from the cohort. Only pregnant women with a registered early-

11

175 pregnancy weight and a height from 120 through 200 cm were included. Maternal BMI was calculated as weight in kilograms divided by the square of the height in meters (kg/m<sup>2</sup>) and BMI 176 177 values are reported in that unit. Extreme observations defined as BMI < 12 and BMI > 60 were excluded to avoid registration errors. 178 179 We identified fetuses and infants with CHDs (Table S1) by using either the prenatal or/and the 180 postnatal diagnoses. In all live births, postnatal CHD diagnoses were considered gold standard. The CHD diagnoses were defined by the European Surveillance of Congenital Anomalies (EUROCAT)<sup>29</sup> 181 (Table S1) and severe CHDs (EUROCAT, Table S1). Severe CHDs include the following 17 diagnoses: 182 truncus arteriosus, double outlet right ventricle, transposition of the great arteries (TGA). 183 univentricular heart (UVH), atrioventricular septum defect (AVSD), Tetralogy of Fallot (ToF), 184 pulmonary atresia, tricuspid valve stenosis, Ebstein's anomaly, hypoplastic right heart syndrome, 185 aortic valve stenosis, mitral valve stenosis, mitral insufficiency, hypoplastic left heart syndrome, 186 187 coarctation of the aorta (CoA), aortic atresia, and total anomalous pulmonary venous return. Irrespective of the number of CHD diagnoses in a particular patient, the patient was only 188 registered once as having CHDs. Furthermore, offspring with five of the most frequent subtypes of 189 severe CHDs were identified (Table S2). These were ranked as defined by Lytzen et al.<sup>27</sup> with the 190 191 most severe first (UVH > TGA > AVSD > CoA > ToF). If offspring had combinations of these subtypes, they were only registered once with the most severe diagnosis. ICD-10 codes for severe 192 CHDs have been validated against hospital records with very good agreement in the Danish 193 National Patient Register.<sup>30</sup> Prenatal diagnoses of 12 severe CHDs have been shown to have a very 194 195 high diagnostic precision.<sup>28</sup>

12

196	For the calculations of interpregnancy BMI changes, a sub-cohort including women with first and
197	second pregnancies and more than 50 weeks between estimated due dates was compiled.
198	Maternal height was defined as the height registered in the first pregnancy. Interpregnancy BMI
199	changes were calculated as the difference between BMI at the beginning of the first and BMI at
200	the beginning of the second pregnancy. Differences were categorized into six groups < -2; -2 to < -
201	1; -1 to < 1; 1 to < 2; 2 to < 4; and ≥4 BMI units. The category -1 to < 1 was defined as stable weight
202	and used as reference.
203	Associations between maternal BMI and offspring risk of CHDs were calculated as risk ratios (RRs)
204	with 95% CI using log-linear Poisson regression models. The models were adjusted for maternal

205 age (<20, 20−24, 25−29, 30−34, 35−39, ≥40 years), maternal smoking status (yes/no/stopped), and

206 year of estimated due date (1-year groups). The model was not adjusted for potential multiple

207 pregnancies for each woman during the study period. Associations between interpregnancy BMI

changes and risk of CHDs were calculated as RRs with 95% CI using log-linear Poisson regression

209 models. Maternal BMI in first pregnancy and maternal age at second pregnancy were considered

possible confounders and were adjusted for in the multivariate model. Statistical analyses were
run in R version 4.2.1. Statens Serum Institut has approval from the Danish Data Protection Agency

to conduct register-based studies, and the project has been approved (journal no. 19/03354 and
20/09279).

### 214 **Results**

The study cohort consisted of 547 178 singleton pregnancies with estimated due dates between June 1, 2008 and June 1, 2018 when pregnancies with chromosomal aberrations and missing data were excluded as detailed in Figure 1. A total of 5 498 (1.0%) offsprings had CHDs. Of these 1 227

13

218	were defined as severe CHDs (0.2%). Clinical and demographic data are available in Table 1.
219	Information on parity was not registered and therefore missing in the dataset from 2008-2011
220	corresponding to 25% of the pregnancies. The study cohort comprised 534 478 live births (97.7%),
221	1 623 stillbirths (0.3%), 5 073 abortions or terminated pregnancies (0.9%), and 6 004 pregnancies
222	with missing outcomes (1.1%). In total, 35% of the women had an early-pregnancy BMI $\geq$ 25, and
223	13% were obese (BMI $\geq$ 30). The distribution of maternal BMI among the different groups and
224	covariates can be seen in Table 1.
225	Maternal overweight was associated significantly with higher risk of CHDs in the offspring
226	increasing with higher maternal BMI: for BMI 25-29.9, adjusted relative risk (aRR) = 1.17 (95% CI
227	1.09-1.25), for BMI 30-34.9, aRR = 1.23 (95% CI 1.12-1.36), for BMI 35-39.9, aRR = 1.26 (95% CI
228	1.09-1.46) and for BMI $\geq$ 40, aRR = 1.81 (95% CI 1.50-2.15) compared to women with an early-
229	pregnancy BMI 18.5-24.9 (Table 2). Similar results were seen for maternal BMI and severe CHDs:
230	for BMI 25-29.9, aRR = 1.20 (95% CI 1.04-1.38), for BMI 30-34.9, aRR = 1.28 (95% CI 1.04-1.56), for
231	BMI 35-39.9, aRR = 1.47 (95% CI 1.09-1.96) and for BMI ≥ 40, aRR = 1.85 (95% CI 1.23-2.67)
232	compared to women with an early-pregnancy BMI 18.5-24.9 (Table 2). A slightly higher risk of
233	CHDs, when only including live births compared to all pregnancies, was seen for maternal BMI $\ge$ 30
234	(aRR 1.24-1.87; data available in Table S3).
235	The proportion of CHD cases with one of the five specific CHD diagnoses were as follows:
236	univentricular heart (UVH; 4.4%), transposition of the great arteries (TGA; 3.2%), atrioventricular

septum defect (AVSD; 4.5%), coarctation of the aorta (CoA; 4.6%), and Tetralogy of Fallot (ToF;

238 2.3%). The association between maternal BMI and these specific five CHD diagnoses are shown in

14

249	Comment
248	remained towards higher risks of any CHDs with weight gain between pregnancies (Table 3).
247	maternal age in the second pregnancy and maternal BMI in the first pregnancy, only a trend
246	significantly associated with higher risk of CHDs in second pregnancy. However, when adjusted for
245	gain between pregnancies (0.8% to 1.3%). Increase in maternal BMI between pregnancies were
244	pregnancy. The prevalence of CHDs in the second pregnancy became higher with increased weight
243	24.9 vs. 25.8 in second pregnancy. In total, 998 had an offspring with CHDs (0.9%) in their second
242	pregnancies between June 1, 2008 and June 1, 2018 (Table 3). Mean BMI in first pregnancy was
241	The sub-cohort included 107 627 women who had a first and second consecutive singleton
240	BMI $\geq$ 30 was associated with a significantly higher risk of AVSD in the offspring (Figure 2).
239	Figure 2. No significant associations were seen for UVH, TGA, CoA and ToF. However, maternal

#### 250 Principal Findings

251 When including both pre- and postnatally diagnosed CHDs, this study showed a dose-response

association between high maternal BMI and risk of CHDs in the offspring. However, only a non-

significant trend was seen between interpregnancy BMI changes between first and second

254 pregnancies and risk of fetal CHDs in the second pregnancies.

#### 255 **Results in the Context of What is Known**

256 This prospective nationwide cohort included 547 178 live births, stillbirths, abortions and

257 terminated pregnancies in Denmark from 2008 to 2018 and showed that maternal overweight and

obesity were significantly associated with a moderately higher risk of CHDs (aRR = 1.17-1.81) and

severe CHDs (aRR = 1.20-1.85) in the offspring compared to women with a BMI in the normal

15

260 range (BMI 18.5-24.9). The study validates previous findings of a positive association between high maternal BMI and risk of CHDs in the offspring<sup>13, 14, 31, 32</sup> and thereby rejects any hypothesis of this 261 262 association to be caused by lower prenatal detection rates of CHDs in pregnant women with obesity. Most other studies have been limited to live births.<sup>15,31</sup> A large nationwide Swedish study 263 264 with two million live born children found a positive association between high maternal BMI and CHDs (BMI 30-34.9: OR = 1.2, 95% CI 1.2–1.3; BMI  $\geq$  40: OR = 1.6, 95% CI 1.4–1.8).<sup>31</sup> When 265 restricting our analysis to live births (Table S3), we found significant associations of a similar 266 267 magnitude between maternal BMI  $\geq$  25 and CHDs. Results from five specific subtypes of CHDs 268 (UVH, TGA, AVSD, CoA and ToF) showed no significant association with maternal BMI except for AVSD (Figure 2), which was significantly associated with increased risks when maternal BMI  $\geq$  30 269 270 (BMI 30 to  $\geq$  40: aRR = 1.65-4.19). Persson et al. found a non-significant trend between maternal BMI and AVSD in women with BMI  $\ge$  30,<sup>5</sup> and the same pattern was observed in other 271 studies.<sup>9,33,34</sup> The lack of statistical significance in other studies might be due to few cases in each 272 BMI group or different study designs. We examined the interpregnancy weight changes between 273 274 the first and second pregnancies in 107 627 women and found a trend towards higher risks of 275 CHDs in second pregnancies preceded by a substantial BMI gain but this was not significant when data was adjusted for maternal BMI in first pregnancy and maternal age in second pregnancy 276 277 (Table 3) as a result of the correlation between maternal BMI and interpregnancy weight changes. The investigations of the association between interpregnancy weight changes and risk of fetal 278 CHDs are sparse.<sup>16</sup> A few studies have looked at other congenital malformations and found a RR = 279 2.3 for isolated cleft palate when maternal BMI increased  $\geq$  3 units,<sup>20</sup> a positive association 280 between spina bifida and interpregnancy BMI gain,<sup>18</sup> and a significant decrease in OR = 0.62 (95%) 281 CI 0.42-0.94) for gastroschisis when maternal BMI increased with  $\geq$  3 units.<sup>19</sup> 282

16

### 283 Clinical Implications

Lifestyle interventions to reduce risk of fetal CHDs have been suggested to be introduced before or between pregnancies.<sup>35</sup> Although our results only indicate a trend between interpregnancy weight changes and risk of CHDs, it does not dismiss a positive effect of weight reduction in women with obesity before pregnancy. In a setting with pre-pregnancy counseling, it is still important to advise women about the importance of BMI as a risk factor for congenital malformations,<sup>5</sup> obstetric and perinatal complications.<sup>3,4</sup>

#### 290 Reseach Implications

291 Prenatal detection rates of congenital malformations decreases with increasing maternal BMI since image quality is lower in women with obesity.<sup>36,37</sup> Consequently, studies only including live 292 293 births could be biased towards a higher postnatal prevalence of CHDs in women with obesity if 294 severe fetal CHDs were not diagnosed and possibly terminated during pregnancy (Table 1). Thus, this phenomenon may at least partly explain a positive association between high BMI and 295 prevalence of CHDs in live borns.<sup>5</sup> Prenatal detection rates of CHDs have improved substantially in 296 297 the last decades, and in countries with prenatal screening with high detection rate of CHDs as in Denmark,<sup>28</sup> it is more important to include terminated pregnancies in prevalence and association 298 studies as the rate of terminated pregnanciess with the most severe CHDs likely will be higher as 299 seen in Table 1. 300

This study confirms the association between high maternal BMI and risk of fetal CHDs. Knowledge about the etiology is still limited<sup>35</sup> and future research should focus on combinations of other related maternal metabolic disorders linked to insulin resistance as suggested in a recent review.<sup>15</sup>

#### 304 Strengths and Limitations

17

305	The strength of this study is the large size of the cohort and prospectively, nationwide data
306	collection including prenatal information. Some limitation must be considered. The database did
307	not include data on pregestational diabetes, which is known to be strongly associated with CHDs,
308	and therefore this confounder was not included as a covariate in the analyses. <sup>15,38</sup> Persson et al.
309	excluded all women with pregestational diabetes and found a moderate association similar to the
310	results of the present study. <sup>31</sup> Nor did the data include information about family history of CHDs, <sup>39</sup>
311	maternal infections or teratogenic medicine intake in pregnancy that have been associated with
312	higher risk of CHDs. <sup>8</sup> Since the study draws conclusions from register data, there is a risk of
313	reporting bias and all CHD diagnoses are not validated against hospital records.
314	Conclusions
315	High maternal BMI is associated with risk of fetal CHDs, and while substantial weight gain between
316	pregnancies may impact the risk, it does not appear to have a significant effect on it.
317	
318	Acknowledgements

- The study group wishes to thank sonographers and medical doctors, who have and continuously
- 320 are collecting data for the Danish Fetal Medicine Database.
- 321 An earlier version of the article is available at a preprint server, MedRxiv
- 322 (https://medrxiv.org/cgi/content/short/2023.02.12.23285811v1).
- 323

# 324 Glossary

18

- 325 AVSD, atrioventricular septum defect
- 326 CHDs, congenital heart defects
- 327 CoA, coarctation of the aorta
- 328 EUROCAT, European Surveillance of Congenital Anomalies
- 329 TGA, transposition of the great arteries
- 330 ToF, Tetralogy of Fallot
- 331 UVH, univentricular heart

19

# 333 References

334	1.	Poston L, Caleyachetty R, Cnattingius S, et al. Preconceptional and maternal obesity:	
335	epidemiolog	y and health consequences. Lancet Diabetes Endocrinol 2016;4:1025-36.	
336	2.	Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity	
337	Among Adul	ts: United States, 2017-2018. NCHS Data Brief 2020;(360):1-8.	
338	3.	Godfrey KM, Reynolds RM, Prescott SL, et al. Influence of maternal obesity on the	
339	long-term he	ealth of offspring. Lancet Diabetes Endocrinol 2017;5:53-64.	
340	4.	Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long	
341	term adverse consequences for mother and child. BMJ 2017;356:j1.		
342	5.	Persson M, Cnattingius S, Villamor E, et al. Risk of major congenital malformations in	
343	relation to n	naternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ	
344	2017;357:j2	563.	
345	6.	Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018	
346	Update: A Report From the American Heart Association. Circulation 2018;137:e67-e492.		
347	7.	Liu Y, Chen S, Zuhlke L, et al. Global birth prevalence of congenital heart defects	
348	1970-2017:	updated systematic review and meta-analysis of 260 studies. Int J Epidemiol	
349	2019;48:455	-63.	
350	8.	Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital	
351	cardiovascu	ar defects: current knowledge: a scientific statement from the American Heart	
352	Association	Council on Cardiovascular Disease in the Young: endorsed by the American Academy	
353	of Pediatrics	. Circulation 2007;115:2995-3014.	

354	9.	Liu S, Joseph KS, Lisonkova S, et al. Association between maternal chronic conditions
355	and congen	ital heart defects: a population-based cohort study. Circulation 2013;128:583-9.
356	10.	Ye Z, Wang L, Yang T, et al. Maternal Viral Infection and Risk of Fetal Congenital Heart
357	Diseases: A	Meta-Analysis of Observational Studies. J Am Heart Assoc 2019;8:e011264.
358	11.	Mamasoula C, Bigirumurame T, Chadwick T, et al. Maternal age and the prevalence
359	of congenit	al heart defects in Europe, 1995-2015: A register-based study. Birth Defects Res
360	2023;115:5	83-94.
361	12.	Pierpont ME, Brueckner M, Chung WK, et al. Genetic Basis for Congenital Heart
362	Disease: Re	visited: A Scientific Statement From the American Heart Association. Circulation
363	2018;138:e	653-e711.
364	13.	Zhu Y, Chen Y, Feng Y, Yu D, Mo X. Association between maternal body mass index
365	and congen	ital heart defects in infants: A meta-analysis. Congenit Heart Dis 2018;13:271-81.
366	14.	Zheng Z, Yang T, Chen L, et al. Increased maternal Body Mass Index is associated with
367	congenital heart defects: An updated meta-analysis of observational studies. Int J Cardiol	
368	2018;273:112-20.	
369	15.	Hedermann G, Hedley PL, Thagaard IN, et al. Maternal obesity and metabolic
370	disorders as	ssociate with congenital heart defects in the offspring: A systematic review. PLoS One
371	2021;16:e0	252343.
372	16.	Bogaerts A, Van den Bergh BRH, Ameye L, et al. Interpregnancy weight change and
373	risk for adve	erse perinatal outcome. Obstet Gynecol 2013;122:999-1009.
374	17.	Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse
375	pregnancy o	outcomes: a population-based study. The Lancet 2006;368:1164-70.

21

376	18.	Benjamin RH, Ethen MK, Canfield MA, Hua F, Mitchell LE. Association of	
-----	-----	--	--

- interpregnancy change in body mass index and spina bifida. Birth Defects Res 2019;111:1389-98.
- 378 19. Benjamin RH, Ethen MK, Canfield MA, Mitchell LE. Change in prepregnancy body
- mass index and gastroschisis. Ann Epidemiol 2020;41:21-7.
- 380 20. Villamor E, Sparen P, Cnattingius S. Risk of oral clefts in relation to prepregnancy
- weight change and interpregnancy interval. Am J Epidemiol 2008;167:1305-11.
- 382 21. Ekelund CK, Kopp TI, Tabor A, Petersen OB. The Danish Fetal Medicine database. Clin
- 383 Epidemiol 2016;8:479-83.
- 384 22. Videbech P, Nielsen J. Electronic data processing in the Danish cytogenetic central

register and EDP problems of registers in general. Clin Genet 1979;15:137-46.

- 386 23. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J
- 387 Public Health 2011;39:30-3.
- 388 24. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998;45:320-3.
- 25. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration
- 390 System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9.
- 391 26. Vedel C, Hjortshoj TD, Jorgensen DS, et al. Prevalence of chromosomal disorders in
- 392 cases with congenital heart defect: registry-based study from Denmark between 2008 and 2018.
- 393 Ultrasound Obstet Gynecol 2023;61:40-48.

27. Lytzen R, Vejlstrup N, Bjerre J, et al. Live-Born Major Congenital Heart Disease in

- 395 Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013.
- 396 JAMA Cardiology 2018;3:829-37.
- 28. Vedel C, Tabor A, Jorgensen FS, et al. Prenatal detection rate of major congenital
  heart defects in Copenhagen from 2015 to 2018. Ultrasound Obstet Gynecol 2021;58:324-5.

399	29.	Greenlees R, Neville A, Addor MC, et al. Paper 6: EUROCAT member registries:
400	organization	and activities. Birth Defects Res A Clin Mol Teratol 2011;91 Suppl 1:S51-S100.
401	30.	Agergaard P, Hebert A, Bjerre J, Sorensen KM, Olesen C, Ostergaard JR. Children
402	diagnosed w	ith congenital cardiac malformations at the national university departments of
403	pediatric car	diology: positive predictive values of data in the Danish National Patient Registry. Clin
404	Epidemiol 20	011;3:61-6.
405	31.	Persson M, Razaz N, Edstedt Bonamy AK, Villamor E, Cnattingius S. Maternal
406	Overweight a	and Obesity and Risk of Congenital Heart Defects. J Am Coll Cardiol 2019;73:44-53.
407	32.	Cai GJ, Sun XX, Zhang L, Hong Q. Association between maternal body mass index and
408	congenital h	eart defects in offspring: a systematic review. Am J Obstet Gynecol 2014;211:91-117.
409	33.	Block SR, Watkins SM, Salemi JL, et al. Maternal pre-pregnancy body mass index and
410	risk of select	ed birth defects: evidence of a dose-response relationship. Paediatr Perinat Epidemiol
411	2013;27:521	-31.
412	34.	Agopian AJ, Moulik M, Gupta-Malhotra M, Marengo LK, Mitchell LE. Descriptive
413	epidemiolog	y of non-syndromic complete atrioventricular canal defects. Paediatr Perinat
414	Epidemiol 20	012;26:515-24.
415	35.	Helle E, Priest JR. Maternal Obesity and Diabetes Mellitus as Risk Factors for
416	Congenital H	eart Disease in the Offspring. J Am Heart Assoc 2020;9:e011541.
417	36.	Best KE, Tennant PW, Bell R, Rankin J. Impact of maternal body mass index on the
418	antenatal de	tection of congenital anomalies. BJOG 2012;119:1503-11.
419	37.	Uhden M, Knippel AJ, Stressig R, et al. Impact of maternal obesity and maternal
420	overweight o	on the detection rate of fetal heart defects and the image quality of prenatal
421	echocardiog	raphy. Ultraschall Med 2011;32 Suppl 2:E108-14.

- 422 38. Oyen N, Diaz LJ, Leirgul E, et al. Prepregnancy Diabetes and Offspring Risk of
- 423 Congenital Heart Disease: A Nationwide Cohort Study. Circulation 2016;133:2243-53.
- 424 39. Brodwall K, Greve G, Leirgul E, Tell GS, Vollset SE, Oyen N. Recurrence of congenital
- heart defects among siblings-a nationwide study. Am J Med Genet A 2017;173:1575-85.

## 427 Tables

## 428 Table 1. Maternal, pregnancy and offspring characteristics in singleton pregnancies in Denmark

## 429 *2008-2018*.

	Pregnancies with	Severe congenital	Pregnancies without			
Charact eristi cs	congenital heart defects	heart defects	congenital heart defects,			
	(EUROCAT), n = 5 498	(EUROCAT), n = 1 227	n = 541 680			
Body mass index, kg/m2	n (%)	n (%)	n (%)			
< 18.5	371 (6.8)	79 (6.4)	35 792 (6.6)			
18.5-<25	2 968 (54.0)	656 (53.5)	318 498 (58.8)			
25-<30	1 2 99 (2 3.6)	289 (23.6)	117 372 (21.7)			
30- <35	531 (9.7)	123 (10.0)	45 927 (8.5)			
35- <40	203 (3.7)	53 (4.3)	16 633 (3.1)			
≥40	126 (2.3)	27 (2.2)	7 458 (1.4)			
Maternal age at						
conception, years						
<20	125 (2.3)	31(2.5)	9 371 (1.7)			
20-24	773 (14.1)	174 (14.2)	70 701 (13.1)			
25-29	1 871 (34.0)	404 (32.9)	184 442 (34.1)			
30-34	1 745 (31.7)	403 (32.8)	181 879 (33.6)			
35-39	843 (15.3)	188 (15.3)	81 370 (15.0)			
≥40	141 (2.6)	27 (2.2)	13 917 (2.8)			
Ethnicity						
Caucasian	5 056 (92.0)	1 134 (92.4)	492 378 (90.9)			
Non-Caucasian	315 (5.7)	73 (5.9)	35 846 (6.6)			
Missing	127 (2.3)	20 (1.6)	13 456 (2.5)			
Smoking status						
No	4 724 (85.9)	1 080 (88.0)	478 823 (88.4)			
Yes	627 (11.4)	115 (9.4)	50 238 (9.3)			
Stopped	92 (1.7)	20 (1.6) 8 765 (1.6)				
Missing	55 (1.0)	12 (1.0)	3 854 (0.7)			

Conception						
pontaneous	4 950 (90.0)	1 117 (91.0)	497 936 (91.9)			
Assisted	463 (8.4)	97 (7.9)	36 516 (6.8)			
Jnknown	85 (1.5)	13 (1.1)	7 228 (1.3)			
Parity						
)	2 046 (37.2)	416 (33.9)	181 065 (33.4)			
1	1571 (28.6)	367 (29.9)	153 479 (28.3)			
2	540 (9.8)	133 (10.8)	53 959 (10.0)			
≥3	203 (3.7)	38 (3.1)	16 653 (3.1)			
Missing	1 138 (20.7)	273 (22.2)	136 524 (25.2)			
Year of estimated due						
date						
2008	216 (3.9)	57 (4.6)	25 266 (4.7)			
2009	477 (8.7)	126(10.3)	56 468 (10.4)			
2010	550 (10.0)	13 1 ( 10. 7)	57 687 (10.7)			
2011	528 (9.7)	120 (9.8)	53 630 (9.9)			
2012	534 (9.7)	137 (11.2)	53 512 (9.9)			
2013	508 (9.2)		51 331 (9.5)			
2014	590 (10.7)	141(11.5)	52 609 (9.7)			
2015	642 (11.7)	137 (11.2)	54 215 (10.0)			
2016	607 (11.0)	110 (9.0)	57 402 (10.6)			
2017	543 (9.9)	101 (8.2)	56 569 (10.4)			
2018	303 (5.5)	47 (3.8)	22 991 (4.2)			
Outcome pregnancy						
Live births	5 187 (94.3)	1 011 (82.4)	529 291 (97.7)			
Stillbirths	41 (0.7)	26 (2.1)	1 582 (0.3)			
Abortions and						
terminated pregnancies	245 (4 5)	175 / 14 - 22	4 010 (0.0)			
after gestational week	245 (4.5)	175 (14.3)	4 828 (0.9)			
12						
Missing	25 (0.5)	15 (1.2)	5 979 (1.1)			
Offspring sex						

26

Male	2 771 (50.4)	624 (50.9)	271 571 (50.1)
Female	2 4 16 (43.9)	387 (31.5)	257 720 (47.6)
Unknown	311 (5.7)	216 (17.6)	12 389 (2.3)

430

431 Abbreviations: EUROCAT, European Surveillance of Congenital Anomalies (diagnoses listed in Table

432 S1)

#### 433 Table 2. Relative risks of congenital heart defects by maternal BMI in 547 178 offsprings (live

	No CHDs		CHDs					Severe CHDs			
Mat erna I	n = 541 680	n = 5 498					n = 1 227				
BMI (kg/m2)	Total	Total	Crude RR	95% Cl	aRR*	95% Cl	Total	Crude RR	95% Cl	aRR*	95% Cl
< 18.5	35 800	371	1.11	1.00-1.24	1.07	0.95-1.19	79	1.07	0.84-1.34	1.02	0.79-1.30
18.5 - 24.9	318 489	2 968	1.00	ref	1.00	ref	656	1.00	ref	1.00	ref
25 - 29.9	117 3 7 3	1299	1.19	1.11-1.27	1.17	1.09-1.25	289	1.19	1.04-1.37	1.20	1.04-1.38
30 - 34.9	45 926	531	1.24	1.13-1.36	1.23	1.12-1.36	123	1.30	1.07-1.57	1.28	1.04-1.56
35 - 39.9	16 635	203	1.31	1.13-1.50	1.26	1.09-1.46	53	1.55	1.15-2.02	1.47	1.09-1.96
≥40	7 4 5 7	126	1.80	1.50-2.14	1.81	1.50-2.15	27	1.76	1.17-2.52	1.85	1.23-2.67

#### 434 *births, stillbirths, abortions and terminated pregnancies), Denmark 2008-2018.*

435

436 Abbreviations: aRR, adjusted relative risk; BMI, body mass index; CHD, congenital heart defects; CI,

437 confidence interval; RR, relative risk.

- 438 \*aRR adjusted for maternal age at conception, smoking status (yes/no/stopped) and year of
- estimated due date comparing CHD risk in women with early-pregnancy BMI < 18.5 kg/m<sup>2</sup> or BMI
- 440  $\geq$  25 kg/m<sup>2</sup> with women with early-pregnancy BMI in the normal range (BMI 18.5-24.9 kg/m<sup>2</sup>).

#### 442 Table 3. Relative risks of congenital heart defects in second pregnancy by interpregnancy maternal

#### BMI changes in 107 627 women with two consecutive singleton pregnancies, Denmark 2008-2018.

BMI change from 1st to 2nd		1st	2nd	Risk of CHDs in 2nd pregnancy						
pregnancy		pregnancy	pregnancy							
Units, kg/m2	No. of women with 1st and 2nd pregnancy (%)	Mean BMI	Mean BMI	n/N	Prevalence of CHDs (%)	Crude RR	95% CI	aRR*	95% C	
<-2	5 941 (5.5)	27.3	24.3	50/5 891	0.8	0.95	0.70-1.26	0.84	0 61 1 12	
-2 to <-1	11 154 (10.4)	24.2	22.8	90/11 064	0.8	0.91	0.72-1.14	0.88	0.70-1.09	
-1to <1	54 154 (50.3)	22.8	22.9	479/53 675	0.9	1.00	ref	1.00	ref	
1to <2	16 940 (15.7)	23.8	25.2	156/16 784	0.9	1.04	0.87-1.24	1.01	0.84-1.21	
2 to <4	14 010 (13.0)	25.0	27.8	155/13 855	1.1	1.25	1.04-1.50	1.17	0 97 1 40	
≥4	5 428 (5.0)	26.3	31.4	68/5360	1.3	1.42	1.09-1.81	1.27	0.96-1.64	
Total	107 627	24.9	25.8	998/106 629	1.0					

444

Abbreviations: aRR, adjusted relative risk; BMI, body mass index; CHDs, congenital heart defects;
CI, confidence interval; n, number of women with their first pregnancy without CHDs and second
pregnancy with CHDs in the offspring; N, number of women with first and second pregnancies
without CHDs; RR, relative risk.

449 \*aRR adjusted for maternal age at conception at second pregnancy and early-pregnancy BMI at


450 1st pregnancy.

29

# 452 Figure Legends

- 453 Figure 1. *Flowchart*.
- 454 Abbreviations: BMI, body mass index; CHDs, congenital heart defects

- 456 Figure 2. Crude relative risks for five subtypes of congenital heart defects by maternal BMI,
- 457 singleton pregnancies in Denmark 2008-2018.
- Body mass index 18.5-24.9 kg/m<sup>2</sup> was considered as the normal range and used as a reference.
- 459 Abbreviations: CHDs, congenital heart defects; CI, confidence interval; RR, relative risk; N, number
- 460 of events



Body mass index	N	RR	95% CI	
Univentricular heart				
< 18.5 18.5 - $29.9$ 30 - 34.9 35 - 39.9 $\geq 40$	12 s version dosted May 19, as granted medRxiv a licer allowed without permission 26 10 3	1.25 2023. The oppyright holder ise to display the preprint in 1.40 1.69 1.79 1.26	0.73-2.39 for this preprint perpetuity. 0.78-2.74 0.87-3.47 0.76-4.16 0.29-3.96	
Transposition of the great arteries				
< 18.5 18.5 - 24.9 25 - 29.9 30 - 34.9 35 - 39.9 ≥ 40	11 98 45 14 6 0	1.00 1.00 1.25 0.99 1.17	0.56-1.98 0.67-2.54 0.45-2.24 0.40-3.08	
Atrioventricular septal defects				
< 18.5 18.5 - 24.9 25 - 29.9 30 - 34.9 35 - 39.9 ≥ 40	16 118 58 28 14 11	1.21 1.00 1.33 1.65 2.27 4.17	0.69-1.97 0.97-1.82 1.07-2.44 1.25-3.81 2.12-7.39	
Coactation of the aorta				
< 18.5 18.5 - 24.9 25 - 29.9 30 - 34.9 35 - 39.9 ≥ 40	14 133 65 23 9 7	0.94 1.00 1.33 1.20 1.30 2.36	0.52-1.57 0.98-1.78 0.75-1.83 0.61-2.40 0.998-4.67	
Tetralogy of Fallot				
< 18.5 18.5 - 24.9 25 - 29.9 30 - 34.9 35 - 39.9 ≥ 40	10 72 24 13 8 2	1.24 1.00 0.90 1.25 2.13 1.25	0.60-2.28 0.56-1.41 0.66-2.18 0.94-4.15 0.20-3.96	0.1 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 Ratios